このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

WuXi Biologics (Cayman) 過去の業績

過去基準チェック /26

WuXi Biologics (Cayman)は、平均年間33.4%の収益成長を遂げていますが、 Life Sciences業界の収益は、年間成長しています。収益は、平均年間22.4% 37.3%収益成長率で成長しています。 WuXi Biologics (Cayman)の自己資本利益率は8.1%であり、純利益率は20%です。

主要情報

33.4%

収益成長率

31.5%

EPS成長率

Life Sciences 業界の成長	41.4%
収益成長率	37.3%
株主資本利益率	8.1%
ネット・マージン	20.0%
前回の決算情報	31 Dec 2023

Recent updates

収支内訳

WuXi Biologics (Cayman) の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

SZSC:2269 収益、費用、利益 ( )CNY Millions
日付	収益	収益	G+A経費	研究開発費
31 Dec 23	17,034	3,400	2,086	786
30 Sep 23	16,794	3,776	2,021	769
30 Jun 23	16,554	4,152	1,956	753
31 Mar 23	15,911	4,286	1,824	718
31 Dec 22	15,269	4,420	1,693	683
30 Sep 22	14,179	4,251	1,472	670
30 Jun 22	13,090	4,081	1,251	657
31 Mar 22	11,690	3,735	1,192	579
31 Dec 21	10,290	3,388	1,133	502
30 Sep 21	9,183	3,092	1,043	398
30 Jun 21	8,075	2,795	952	295
31 Mar 21	6,844	2,242	837	299
31 Dec 20	5,612	1,689	722	304
30 Sep 20	4,967	1,494	648	289
30 Jun 20	4,321	1,300	574	275
31 Mar 20	4,152	1,157	512	267
31 Dec 19	3,984	1,014	451	260
30 Sep 19	3,535	922	427	241
30 Jun 19	3,087	831	404	222
31 Mar 19	2,811	731	365	196
31 Dec 18	2,534	631	326	169
30 Sep 18	2,277	520	270	132
30 Jun 18	2,019	410	214	94
31 Mar 18	1,819	331	195	84
31 Dec 17	1,619	253	175	74
30 Sep 17	1,429	177	155	66
30 Jun 17	1,233	149	128	60
31 Mar 17	1,111	145	119	56
31 Dec 16	989	141	110	53
30 Sep 16	889	171	101	61
31 Dec 15	557	45	86	40
31 Dec 14	332	42	48	35

質の高い収益: 2269は高品質の収益を持っています。

利益率の向上: 2269の現在の純利益率 (20%)は、昨年(29%)よりも低くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 2269の収益は過去 5 年間で年間33.4%増加しました。

成長の加速: 2269は過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: 2269は過去 1 年間で収益成長率がマイナス ( -23.1% ) となったため、 Life Sciences業界平均 ( 0.7% ) と比較することが困難です。

株主資本利益率

高いROE: 2269の自己資本利益率 ( 8.1% ) は低いとみなされます。

WuXi Biologics (Cayman) 過去の業績

過去 基準チェック /26

主要情報

最近の業績更新

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

First half 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in 1H 2022)

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

Full year 2022 earnings released: EPS: CN¥1.06 (vs CN¥0.81 in FY 2021)

Recent updates

CEO & Executive Director recently sold HK$6.6m worth of stock

Investor sentiment deteriorates as stock falls 16%

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

Investor sentiment deteriorates as stock falls 17%

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

Investor sentiment deteriorates as stock falls 18%

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

Investor sentiment deteriorates as stock falls 19%

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

Independent Non-Executive Director recently bought HK$3.0m worth of stock

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Investor sentiment improves as stock rises 16%

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 28%

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

Now 21% undervalued

Board Member recently sold HK$25m worth of stock

Now 21% undervalued

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Investor sentiment improves as stock rises 16%

First half 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in 1H 2022)

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

CEO & Executive Director recently sold HK$4.6m worth of stock

Investor sentiment deteriorates as stock falls 20%

CEO & Executive Director recently sold HK$13m worth of stock

Now 21% undervalued after recent price drop

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

Now 20% undervalued after recent price drop

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Now 20% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Now 20% undervalued after recent price drop

Full year 2022 earnings released: EPS: CN¥1.06 (vs CN¥0.81 in FY 2021)

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Investor sentiment improved over the past week

Now 22% undervalued after recent price drop

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021)

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

Now 21% undervalued

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

CEO & Executive Director recently sold HK$17m worth of stock

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS: CN¥0.81 (vs CN¥0.43 in FY 2020)

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Wuxi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Ended December 31, 2021

CEO & Executive Director recently bought HK$18m worth of stock

CEO & Executive Director recently bought HK$21m worth of stock

WuXi Biologics Announces Completion of GMP Production At 24,000L Line of Its Drug Substance Facility MFG5

過去基準チェック /26